Britain and America have hammered out a significant trade agreement that will maintain zero levies on UK pharmaceutical shipments entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to raise spending on drugs through the National Health Service (NHS). This commitment secures that import taxes on these crucial goods will be held at zero for a period of the next three years.
This development comes after previous statements to hike import taxes on branded pharmaceutical products, with figures floated as high as 100%.
"This arrangement with the Britain bolsters the global environment for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," an announcement declared.
Commercial Importance
Pharmaceuticals are one of the UK's largest exports to the United States, which is by far the largest market for major British pharmaceutical firms.
Statistics indicate that in the 12 months leading up to September, the UK exported drugs totaling £11.1bn to the US. This value made up a significant portion of total UK exports in that span.
"This agreement safeguards jobs, stimulates funding and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Key NHS Changes
The pact includes several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at 15%. Previously, refunds exceeded 20%.
Broader Context
This agreement comes amid a long-running tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
This friction were exacerbated by arguments that US customers were paying significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official acknowledged that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
